Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study

Autor: Camelo, R.M., Dias, M.M., Caram-Deelder, C., Gouw, S., Magalhaes, L.P. de, Zuccherato, L.W., Jardim, L.L., Oliveira, A.G. de, Ribeiro, R.D., Franco, V.K.B., Roberti, M.D.F., Callado, F.M.R.D., Etto, L.Y., Cerqueira, M.A.F. de, Cerqueira, M.H., Lorenzato, C.S., Souza, I.S. de, Serafim, E.S.S., Garcia, A.A., Anegawa, T.H., Neves, D.C.F., Tan, D.M., Bom, J. van der, Rezende, S.M., Brazilian Immune Tolerance BraziT

Publikováno v: Journal of Thrombosis and Haemostasis, 20(11), 2526-2537. WILEY
Journal of thrombosis and haemostasis, 20(11), 2526-2537. Wiley-Blackwell

Background Immune tolerance induction (ITI) is the treatment of choice for eradication of anti-factor VIII (FVIII) neutralizing alloantibodies (inhibitors) in people with inherited hemophilia A and high-responding inhibitor (PwHA-HRi). The associatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67662ef49ec734b525055769692a1730
https://doi.org/10.1111/jth.15878